CLINICAL STUDY
Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure
W. H. Wilson Tang, MD*,
Randall H. Vagelos, MD*,
Yin-Gail Yee, BS*,
Claude R. Benedict, MD ,
Kathy Willson, RN*,
Charles L. Liss, MS ,
Patrice LaBelle, MD and
Michael B. Fowler, MBBS, FRCP, FACC*,*
* Stanford University Medical School, Stanford, California, USA
University of Texas Medical School, Houston, Texas, USA
Merck & Co., West Point, Pennsylvania, USA
Manuscript received November 10, 2000;
revised manuscript received August 3, 2001,
accepted October 11, 2001.
* Reprint requests and correspondence: Dr. Michael B. Fowler, Falk-CVRC 295, Stanford University Medical Center, Stanford, California 94305 USA.
mfowler{at}stanford.edu
OBJECTIVES: We sought to compare the neurohormonal responses and clinical effects of long-term, high-dose versus low-dose enalapril in patients with chronic heart failure (CHF).
BACKGROUND: Examination of neurohormonal and clinical responses in patients receiving different doses of angiotensin-converting enzyme (ACE) inhibitors may provide insight into the potential for additional suppression with angiotensin II (AT-II) or aldosterone antagonists.
METHODS: Seventy-five patients with CHF were randomized to receive either high-dose (40 mg/day, n = 37) or low-dose (5 mg/day, n = 38) enalapril over six months. The results from exercise testing, echocardiography, tissue-specific ACE activity and monthly pre- and post-enalapril neurohormonal levels were compared.
RESULTS: Despite greater intra-group improvements in plasma renin activity and serum aldosterone levels in the high-dose group, no statistically significant differences were observed between the two groups in all variables, except for serum ACE activity at the end of study. Elevated serum aldosterone and plasma AT-II levels were observed in 35% and 85% of patients, respectively, at 34 weeks, an inter-group difference that was not statistically significant. A trend toward higher levels of tissue-specific ACE activity in the high-dose group compared with the low-dose group at the end of study was observed (p = 0.054). A predefined composite end point of clinical events had a trend toward better improvement in the high-dose group.
CONCLUSIONS: This study could not demonstrate a difference between high- and low-dose enalapril in terms of serum aldosterone and plasma AT-II suppression, despite a dose-dependent reduction in serum ACE activity. Even at maximal doses of enalapril, elevated serum aldosterone and plasma AT-II levels were frequently observed.
|
Abbreviations and Acronyms
| | ACE | | angiotensin-converting enzyme | | AT-II | | angiotensin II | | ARB | | angiotensin II receptor blocker | | CHF | | chronic heart failure | | NYHA | | New York Heart Association | | RAA | | renin-angiotensin-aldosterone |
|
This article has been cited by other articles:
|
|
|
|
 
H. Krum
Role of renin in heart failure and therapeutic potential of direct renin inhibition
Journal of Renin-Angiotensin-Aldosterone System,
September 1, 2008;
9(3):
177 - 180.
[PDF]
|
|
|
|
|
|
|
C. O. Phillips, A. Kashani, D. K. Ko, G. Francis, and H. M. Krumholz
Adverse Effects of Combination Angiotensin II Receptor Blockers Plus Angiotensin-Converting Enzyme Inhibitors for Left Ventricular Dysfunction: A Quantitative Review of Data From Randomized Clinical Trials
Arch Intern Med,
October 8, 2007;
167(18):
1930 - 1936.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Klotz, A.H. J. Danser, R. F. Foronjy, M. C. Oz, J. Wang, D. Mancini, J. D'Armiento, and D. Burkhoff
The Impact of Angiotensin-Converting Enzyme Inhibitor Therapy on the Extracellular Collagen Matrix During Left Ventricular Assist Device Support in Patients With End-Stage Heart Failure
J. Am. Coll. Cardiol.,
March 20, 2007;
49(11):
1166 - 1174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. H. W. Tang, A. C. Parameswaran, A. P. Maroo, and G. S. Francis
Aldosterone Receptor Antagonists in the Medical Management of Chronic Heart Failure
Mayo Clin. Proc.,
December 1, 2005;
80(12):
1623 - 1630.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Abdulla, S. Z. Abildstrom, E. Christensen, L. Kober, and C. Torp-Pedersen
A meta-analysis of the effect of angiotensin-converting enzyme inhibitors on functional capacity in patients with symptomatic left ventricular systolic dysfunction
Eur J Heart Fail,
December 1, 2004;
6(7):
927 - 935.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. McNamara, R. Holubkov, L. Postava, K. Janosko, G. A. MacGowan, M. Mathier, S. Murali, A. M. Feldman, and B. London
Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure
J. Am. Coll. Cardiol.,
November 16, 2004;
44(10):
2019 - 2026.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. N. Gring and G. S. Francis
A hard look at angiotensin receptor blockers in heart failure
J. Am. Coll. Cardiol.,
November 2, 2004;
44(9):
1841 - 1846.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S Roffman
High-Versus Low-Dose ACE Inhibitor Therapy in Chronic Heart Failure
Ann. Pharmacother.,
May 1, 2004;
38(5):
831 - 838.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Jessup and S. Brozena
Heart Failure
N. Engl. J. Med.,
May 15, 2003;
348(20):
2007 - 2018.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Mehra, P. A. Uber, and G. S. Francis
Heart failure therapy at a crossroad: are there limits to the neurohormonal model?
J. Am. Coll. Cardiol.,
May 7, 2003;
41(9):
1606 - 1610.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Sato, K. Hayashi, M. Naruse, and T. Saruta
Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy
Hypertension,
January 1, 2003;
41(1):
64 - 68.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R.N. Doughty and N. Sharpe
Optimization of ACE inhibitor therapy in heart failure
Eur. Heart J.,
September 1, 2002;
23(17):
1322 - 1323.
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. P. Jorde, T. Vittorio, S. D. Katz, P. C. Colombo, F. Latif, and T. H. Le Jemtel
Elevated Plasma Aldosterone Levels Despite Complete Inhibition of the Vascular Angiotensin-Converting Enzyme in Chronic Heart Failure
Circulation,
August 27, 2002;
106(9):
1055 - 1057.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
ACE-Inhibitor Dose Level Does Not Affect Neurohormonal Blockade in Heart Failure
Journal Watch Cardiology,
April 12, 2002;
2002(412):
5 - 5.
[Full Text]
|
|
|
|
|
|
|
B. M. Massie
Neurohormonal blockade in chronic heart failure: How much is enough? can there be too much?
J. Am. Coll. Cardiol.,
January 2, 2002;
39(1):
79 - 82.
[Full Text]
[PDF]
|
|
|
|
